Evidence map›Paper›PMID 37321487›Full record

ArticleAntiviral research2023

Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV.

Yu-Jen Chang, Uyen Nguyen Phuong Le, Jia-Jun Liu, Sin-Rong Li, Shao-Ting Chao, Hsueh-Chou Lai, Yu-Feng Lin, Kai-Cheng Hsu, Chih-Hao Lu, Cheng-Wen Lin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Yu-Jen ChangThe Ph.D. Program of Biotechnology and Biomedical Industry, China Medical University, Taichung, Taiwan.
Uyen Nguyen Phuong LeDepartment of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan; Graduate Institute of Biological Sciences and Technology, China Medical University, Taichung, Taiwan.
Jia-Jun LiuGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Sin-Rong LiDepartment of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan; Department of Laboratory Medicine, China Medical University Hospital, Taichung, Taiwan.
Shao-Ting ChaoDepartment of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan.
Hsueh-Chou LaiDivision of Hepato-Gastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Yu-Feng LinDepartment of Medical Laboratory Science and Biotechnology, Asia University, Taichung, Taiwan.
Kai-Cheng HsuGraduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan.
Chih-Hao LuThe Ph.D. Program of Biotechnology and Biomedical Industry, China Medical University, Taichung, Taiwan; Institute of Bioinformatics and Systems Biology, National Yang Ming Chiao Tung University, Hsinchu, Taiwan; Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu, Taiwan. Electronic address: chlu@nycu.edu.tw.
Cheng-Wen LinThe Ph.D. Program of Biotechnology and Biomedical Industry, China Medical University, Taichung, Taiwan; Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan; Graduate Institute of Biological Sciences and Technology, China Medical University, Taichung, Taiwan; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung, Taiwan. Electronic address: cwlin@mail.cmu.edu.tw.
China Medical University · TWAsia University · TWNational Yang Ming Chiao Tung University · TWTaipei Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main protease (M

Indexed as

COVID-19Middle East Respiratory Syndrome CoronavirusAntiviral AgentsCysteine EndopeptidasesHumansMolecular Docking SimulationProtease InhibitorsSARS-CoV-2Antiviral AgentsCysteine EndopeptidasesProtease Inhibitorscis-/trans-cleavage assayIn-silico predictionMain proteaseMERS-CoVNational cancer institute databaseSARS-CoV-2

Identifiers

PMID37321487
PMCPMC10264167
OpenAlexW4380793052

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.